A Method of Tumor In Vivo Imaging with a New Peptide-Based Fluorescent Probe.
A Method of Tumor In Vivo Imaging with a New Peptide-Based Fluorescent Probe.
复制标题
DOI：
10.1007/978-1-0716-1811-0_45
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Yamada T
中科院分区：
文献类型：
--
作者：
Naffouje S;Goto M;Ryoo I;Green A;Das Gupta TK;Yamada T
精准的手术切除直接影响实体瘤患者的预后和生存。然而，在没有任何术中影像指导的情况下，在切除过程中通常很难区分肿瘤与正常组织。图像引导手术，特别是与近红外 (NIR) 荧光剂结合使用时，可以提高切缘阳性率，从而改善总体预后。我们开发了一种独特的肿瘤靶向荧光成像剂，可以帮助在临床前环境中准确定位人类癌细胞。近红外成像剂ICG-p28是一种水溶性、无毒、全肿瘤靶向探针，由与吲哚菁绿（ICG）缀合的细胞穿透肽（p28）组成，可以在体内准确定位肿瘤。非侵入性靶向显像剂的开发可以通过定位目前难以或不可能通过视觉观察或触诊检测到的病变来改善肿瘤的切除。在这里，我们描述了使用近红外荧光成像仪与新型肿瘤靶向剂结合的临床前动物成像模型的方法。
Precise surgical resection directly influences the prognosis and survival of patients with solid tumors. However, it is often difficult to distinguish tumor from normal tissue during resection without any intraoperative imaging guidance. Image-guided surgery particularly when coupled with a near-infrared (NIR) fluorescent agent may improve positive-margin rate thereby improving the overall prognosis. We have developed a unique tumor-targeting fluorescence imaging agent that can aid in the accurate localization of human cancer cells in preclinical settings. The NIR imaging agent, ICG-p28, a water-soluble, nontoxic, and pan-tumor targeting probe consisting of a cell-penetrating peptide (p28) conjugated to indocyanine green (ICG), can accurately localize tumors in vivo. Development of the noninvasive, targeted imaging agent can potentially improve in the resections of tumors by enabling the localization of lesions that are currently difficult or impossible to detect by visual observation or palpation. Here, we describe the methods of preclinical animal imaging models by using NIR fluorescence imager coupled with a new tumor-targeting agent.